Twin Peaks Wealth Advisors’s Solid Biosciences SLDB Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$36	–	1870
2026 Q1	$36	Buy	+5	New	+$32	﹤0.01%	2320

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Twin Peaks Wealth Advisors's SLDB Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 5 shares — an estimated $36 sold.

Twin Peaks Wealth Advisors first reported a position in SLDB in Q1 2026 and held it in 1 quarter. The position peaked at $36 in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 5 Solid Biosciences shares in Q2 2026, an estimated $36.
Twin Peaks Wealth Advisors first reported a position in Solid Biosciences in Q1 2026 and held it in 1 quarter.
Twin Peaks Wealth Advisors's Solid Biosciences position peaked at $36 in Q1 2026.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.